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SPHERE 12 Screening Questionnaire
Description
The SPHERE 12 (Somatic and Psychological HEalth REport) 
is a 12-item, self-rated tool to screen for anxiety, depression, 
and somatisation in primary care. The SPHERE 12 is a 
shortened version of the SPHERE 34 (Hickie et al 2001a), 
which was derived from the General Health Questionnaire 
(GHQ-30), the Schedule of Fatigue and Anergia, the Illness, 
Fatigue and Irritability Questionnaire, and the Diagnostic 
Interview Schedule for somatisation. Six items of the SPHERE 
12 assess psychological health (PSYCH subscale) and six 
assess physical symptoms and fatigue (SOMA subscale).
Instruction to the patient and scoring: Patients rate the 
PSYCH and SOMA items in terms of how much each has 
troubled them over the past few weeks on a scale of 0–2 (0 = 
never troubled, 2 = troubled most of the time). A score of two 
or more on the PSYCH subscale reﬂects the presence of a 
possible mental disorder (anxiety or depression) and three or 
more on the SOMA subscale reﬂects the presence of a possible 
somatic disorder (somatoform disorder or somatisation) 
(Hickie et al 2001a, Wilhelm et al 2008). Positive scores on 
both scales reﬂect a mixed presentation. The SPHERE 12 
can be used as a broad or a narrow screening tool: the broad 
screen requires a positive score on PSYCH and/or SOMA 
subscales, while the narrow screen requires a positive score 
on both PSYCH and SOMA subscales.
Clinimetric: The SPHERE 12 has high internal consistency 
(PSYCH 0.90, SOMA 0.80) and test-retest reliability 
(PSYCH 0.81, SOMA 0.80) in general practice (Hickie 
et al 2001a, Hickie et al 2001b). When detecting lifetime 
occurrence of any mental disorder in a young adult 
community sample, trained psychologists found fair 
agreement (kappa = 0.39) between the broad screen (a 
positive score on PSYCH and/or SOMA) of the SPHERE 
12 and the Composite International Diagnostic Interview 
(CIDI) (the gold standard for psychiatric diagnosis) 
(McFarlane et al 2008). The same study also reported an 
area under the Receiver Operator Curve (ROC) of 72.9 
for the PSYCH subscale and 71.5 for the SOMA subscale. 
Substantial agreement was found between the PSYCH 
subscale and the HADS (Hospital Anxiety and Depression 
Scale) when the threshold score was 2 (kappa = 0.67) or 3 
(kappa = 0.73) in a sample of cancer patients (Clover et al 
2009). When the broad screen is used in general practice, 
it has high sensitivity (93%) and low speciﬁcity (20%), 
for detecting mental disorders. If the narrow screen (a 
positive score on PSYCH and SOMA subscales) is used, 
the SPHERE 12 shows a low sensitivity (47%) and high 
speciﬁcity 72% (Clarke and McKenzie 2002).
Commentary
Early identiﬁcation of mental health disorders is essential 
for optimum patient care. The most appropriate setting for 
early detection is primary care. Physiotherapists in primary 
care are commonly exposed to patients with diagnostic 
labels such as chronic fatigue syndrome or ongoing, 
unexplained pain. Epidemiological and genetic research 
has shown that there are strong links between non-speciﬁc 
somatic symptoms and anxiety and depression (Hansell 
et al 2011, Katon et al 2007) and this may lead to these 
disorders being missed (McFarlane et al 2008).
Using a tool to screen for mental disorders is likely to help 
early identiﬁcation and improved care. The SPHERE 12 is 
a potentially good candidate for this role because it is easy 
to apply and brief. The broad screen also has the advantage 
of high sensitivity, which means that ‘at risk cases’ are 
unlikely to be missed. However, it also has low speciﬁcity 
and only fair validity when compared with the CIDI, the 
gold standard of psychiatric diagnosis. This combination 
of features indicates a signiﬁcant number of false positive 
‘cases’ will be identiﬁed using the SPHERE 12 screen and 
this could lead to unnecessary and costly investigations 
(Phillips et al 2002).
Consideration of a number of factors might make this tool 
more appealing to the primary care clinician. First, the 
suggested thresholds may not be the most appropriate to 
detect different mental health disorders in the primary care 
setting, (see Table in McFarlane et al 2008 p. 341). There is 
therefore a need to determine unique threshold values for 
each mental health disorder and apply these values when 
using the SPHERE 12 (McFarlane et al 2008, Clover et al 
2009). Second, speciﬁcity may be improved by using the 
narrowest screen of SHERE 12 along with an additional tool 
such as the SF-12 Mental Component Scale, as suggested 
by Wilhelm et al (2008). Third, some further research is 
needed into the validity of the SPHERE 12 in different 
patient populations. Finally, clinicians should regard the 
SPHERE 12 primarily as a screening tool and the scores 
should be used to direct further investigations into the 
presenting signs and symptoms, rather than to diagnose 
mental disorders.
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